公开(公告)号：US20240335379A1

公开(公告)日：2024-10-10

申请号：US18293826

申请日：2022-08-05

申请人： ZYDUS LIFESCIENCES LIMITED

发明人： Kannan Essakimuthu MUTHAIYYAN ,  Debjani Manoj SINGH ,  Tushar Surajmal NAHATA ,  Abhilash Reddy JONNALA ,  Achuth Devadas SHENOY ,  Darshan Dineshchandra DARJI

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K31/473 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26

CPC分类号： A61K9/08 ,  A61K9/0019 ,  A61K31/473 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/20 ,  A61K47/26

摘要： The present invention provides a stable pharmaceutical composition comprising apomorphine and one or more pharmaceutically acceptable carriers in an injectable device. The present invention also provides a process for preparing the stable pharmaceutical composition.

公开(公告)号：US20240335375A1

公开(公告)日：2024-10-10

申请号：US18294739

申请日：2022-08-03

申请人： BIOADHESIVE OPHTHALMICS ,  UNIVERSITÉ DE LORRAINE

发明人： Jean CUINE ,  Boris BIZET ,  Frédéric LALLEMAND ,  Jean GARREC ,  Stéphane GIBAUD ,  Anne SAPIN-MINET

IPC分类号： A61K9/00 ,  A61K45/06 ,  A61K47/36

CPC分类号： A61K9/0048 ,  A61K45/06 ,  A61K47/36

摘要： An ocular delivery system useful for the treatment of glaucoma in subject in need thereof. Especially, a mucoadhesive solid or semisolid ocular delivery system that includes a matrix of preactivated thiomer of hyaluronic acid and one or more anti-glaucoma drugs. The ocular delivery system may be an ocular insert or an ocular film.

公开(公告)号：US20240335371A1

公开(公告)日：2024-10-10

申请号：US18296940

申请日：2023-04-06

申请人： State-of-the-Art Technologies, Inc.

发明人： Sota Osemwota Omoigui

IPC分类号： A61K9/00 ,  A61K9/107 ,  A61K31/352 ,  A61K33/06 ,  A61K36/53 ,  A61K47/14 ,  A61K47/34

CPC分类号： A61K9/0034 ,  A61K9/0014 ,  A61K9/107 ,  A61K31/352 ,  A61K33/06 ,  A61K36/53 ,  A61K47/14 ,  A61K47/34

摘要： Compositions and methods include magnesium sulfate or forskolin to treat erectile dysfunction, premature ejaculation, decreased libido, and benign prostatic hyperplasia in the male and orgasmic sexual dysfunction/decreased libido in the female. The compositions may be delivered topically or transdermally on the penis to reduce the symptoms of erectile dysfunction, premature ejaculation, low libido, by increasing blood flow to the penis, delivered topically in the ano-rectal or prostate region to reduce the symptoms of BPH by smooth muscle relaxation of the prostate, or by topical or transdermal application to the female genitalia, nipple and/or ano-rectal region, to treat low libido/orgasmic sexual dysfunction.

公开(公告)号：US12110318B2

公开(公告)日：2024-10-08

申请号：US17837736

申请日：2022-06-10

申请人： Adepthera LLC

发明人： Sheau Yu Teddy Hsu

IPC分类号： C07K14/575 ,  A61K38/00 ,  A61K45/06 ,  A61K47/54 ,  A61K47/60 ,  C07K14/47 ,  C07K14/585 ,  C07K14/655 ,  A61K9/00

CPC分类号： C07K14/575 ,  A61K45/06 ,  A61K47/542 ,  A61K47/60 ,  C07K14/47 ,  C07K14/57527 ,  C07K14/585 ,  C07K14/655 ,  A61K9/0019 ,  A61K38/00 ,  C07K2319/00

摘要： Analogs for CLR/RAMP receptor ligands are provided that have agonist, superagonist, antagonist, super-antagonist, or multiple receptor modulating activity. The analogs can be selective for one or more CLR/RAMP receptors, or can be pan-specific for multiple G protein-coupled receptors.

公开(公告)号：US12110297B2

公开(公告)日：2024-10-08

申请号：US18329986

申请日：2023-06-06

申请人： AbbVie Inc.

发明人： Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ben Klünder

IPC分类号： C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04

CPC分类号： C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04 ,  C07B2200/13

摘要： The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US12109324B2

公开(公告)日：2024-10-08

申请号：US16698245

申请日：2019-11-27

申请人： Samuel E. Lynch

发明人： Samuel E. Lynch ,  Leslie Wisner-Lynch

IPC分类号： A61K38/18 ,  A61K9/00 ,  A61K9/70 ,  A61K47/34 ,  A61K47/42 ,  A61L26/00 ,  A61P17/02

CPC分类号： A61L26/0066 ,  A61K9/0014 ,  A61K9/0024 ,  A61K9/7007 ,  A61K38/1858 ,  A61K47/34 ,  A61K47/42 ,  A61L26/0023 ,  A61L26/0033 ,  A61L26/0052 ,  A61L26/0085 ,  A61L26/0095 ,  A61P17/02 ,  A61L2300/414 ,  Y02A50/30

摘要： Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using doing procedures leading to effective results with a minimal number of treatment applications are also described.

公开(公告)号：US12109318B1

公开(公告)日：2024-10-08

申请号：US18489631

申请日：2023-10-18

申请人： MJS Solutions, LLC

发明人： Jamie Lynn Shultz

IPC分类号： A61K9/70 ,  A61K9/00

CPC分类号： A61K9/7084 ,  A61K9/0014

摘要： Devices, groups of devices, kits, and methods for using the devices and kits to administer a local anesthetic to a port site to numb the site prior to infusion or blood draw are described. The devices contain a flexible material with an adhesive coating on one side and a compartment for containing the medication. The device can be pre-filled or a fillable device. In fillable devices, the local anesthetic is transferred from a container into the compartment of the device via the inlet after the device is applied to the patient's skin. In pre-filled devices, the local anesthetic is inside the compartment and is covered with a removable layer to keep it sterile until use. When applied to the patient's skin, the device conforms to the surface of the patient's skin forming a seal keeping the medication in contact with port site.

公开(公告)号：US12109308B2

公开(公告)日：2024-10-08

申请号：US15734147

申请日：2019-06-04

申请人： Pfizer Inc.

发明人： James Joseph Hussey ,  Andrew Gilbert Bright

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  A61P35/00

CPC分类号： A61K9/08 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  A61P35/00

摘要： The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US12109267B2

公开(公告)日：2024-10-08

申请号：US17979309

申请日：2022-11-02

申请人： Fresenius Kabi Deutschland GmbH

发明人： Gianluca Rinaldi ,  Silvia Fratarcangeli ,  Alessandra Del Rio

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K47/18 ,  A61K47/26 ,  C07K16/24

CPC分类号： A61K39/39591 ,  A61K9/0019 ,  A61K47/183 ,  A61K47/26 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/76

摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.

公开(公告)号：US12109216B2

公开(公告)日：2024-10-08

申请号：US18421914

申请日：2024-01-24

申请人： Essentialis, Inc.

发明人： Neil M. Cowen

IPC分类号： A61K31/549 ,  A61K9/00 ,  A61K9/20 ,  A61K9/50 ,  A61K31/137 ,  A61K31/155 ,  A61K31/551 ,  A61K38/27 ,  A61K45/06 ,  C07D285/18 ,  C07D285/22

CPC分类号： A61K31/549 ,  A61K9/00 ,  A61K9/0004 ,  A61K9/2054 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K31/137 ,  A61K31/155 ,  A61K31/551 ,  A61K38/27 ,  A61K45/06 ,  C07D285/18 ,  C07D285/22 ,  A61K2300/00 ,  A61K31/549 ,  A61K2300/00 ,  A61K38/27 ,  A61K2300/00 ,  A61K31/155 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00

摘要： Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.